Treatment for Chickenpox
For otherwise healthy children, chickenpox requires only supportive care with symptomatic treatment; oral acyclovir is not routinely recommended despite modest benefits. However, antivirals should be initiated within 24 hours of rash onset for high-risk groups including adolescents ≥13 years, immunocompromised patients, neonates with perinatal exposure, and those with chronic skin/lung conditions 1, 2.
Treatment Approach for Healthy Children
For immunocompetent children under 13 years:
- Symptomatic treatment only is the standard approach 1
- Antipyretics for fever (avoid aspirin due to Reye syndrome risk)
- Antihistamines or calamine lotion for pruritus
- Maintain hydration
The rationale against routine acyclovir use: While oral acyclovir reduces fever duration by approximately 1 day and decreases maximum lesion count by 15-30%, it does not reduce acute complications, pruritus, viral spread, or school absence duration 1. The marginal therapeutic benefit, combined with cost and the logistical challenge of initiating treatment within the critical 24-hour window, makes routine use impractical 1.
Indications for Antiviral Therapy
Acyclovir 800 mg orally 4 times daily for 5 days (or weight-based dosing in children) should be initiated within 24 hours of rash onset for:
High-Risk Groups Requiring Treatment:
Adolescents and adults ≥13 years - Disease is significantly more severe with higher lesion counts (421 vs 347), greater constitutional symptoms, and more residual scarring compared to younger children 2, 1
Immunocompromised patients - Substantially reduced morbidity and mortality when acyclovir is started early 3
Neonates with perinatal exposure - When maternal chickenpox develops between 7 days before delivery and 7 days after delivery (expanded from previous 5 days before to 2 days after) 4, 5
Chronic conditions - Children >12 months with chronic cutaneous or pulmonary disorders, or those on long-term salicylate therapy 1
Pregnant women with complications - Oral acyclovir 800 mg 5 times daily for significant infection; IV acyclovir 10-15 mg/kg every 8 hours for varicella pneumonitis 5
Critical Timing Considerations
The 24-hour window is essential - Delaying therapy beyond the first 24 hours of rash onset results in loss of therapeutic effect 1. This creates a practical challenge since parents must recognize the rash immediately and access medical care rapidly.
Management of Complications
Bacterial superinfection is the most common complication requiring intervention:
- Co-amoxiclav is frequently used in adults
- Ceftriaxone is commonly used in children 6
- Monitor for signs of secondary bacterial infection of skin lesions
For severe complications (e.g., pneumonitis, encephalitis):
- Hospital admission should be strongly considered
- IV acyclovir 500 mg/m² or 10-15 mg/kg every 8 hours for 5-10 days
- Start within 24-72 hours of rash onset for pneumonitis 5
Post-Exposure Prophylaxis
Varicella zoster immunoglobulin (VZIG) should be administered:
- Within 10 days of exposure (expanded from previous 96-hour window) 4
- For non-immune pregnant women after exposure 5
- For neonates when maternal disease onset is 7 days before to 7 days after delivery 4
Post-exposure vaccination can prevent or modify disease if given within 3-5 days of exposure in susceptible individuals 7.
Common Pitfalls to Avoid
- Do not use aspirin - Risk of Reye syndrome in children with varicella
- Do not delay antiviral therapy in high-risk patients waiting for "confirmation" - clinical diagnosis is sufficient
- Do not assume vaccination equals immunity - breakthrough infections occur, though typically milder
- Do not dismiss adolescent/adult chickenpox as benign - these patients warrant antiviral treatment given significantly worse disease severity 2
The evidence consistently shows that while acyclovir provides modest benefits in healthy children, the therapeutic impact is most clinically meaningful in high-risk populations where early initiation substantially reduces morbidity and mortality 3.